Herpes zoster development in living kidney transplant recipients receiving low‐dose rituximab
International Journal of Urology · 2025
DOI: 10.1111/iju.15600 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Hayato Nishida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan. Hauptthemen laut MEDLINE: Rituximab, Kidney Transplantation, Herpes Zoster. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
We evaluated whether a history of low‐dose rituximab treatment affected herpes zoster development after living kidney transplantation.
Methods
We enrolled 103 living kidney transplant recipients. Patients were divided into two groups according to their history of rituximab treatment; rituximab was administered to 50 living kidney transplant recipients. We assessed the difference in herpes zoster events between the two groups and determined the risk factors for herpes zoster using multivariate regression analysis.
Results
The total dose of rituximab in each kidney transplant recipient who received rituximab therapy was 200–400 mg. The rate of herpes zoster events after transplantation in recipients who received rituximab therapy (4 of 50, 8%) was not higher than that in recipients who did not receive rituximab (9 of 53, 17%) ( p = 0.238). Herpes zoster‐free survival did not significantly differ between the two groups ( p = 0.409). In the multivariate regression analysis, the association between varicella zoster vaccination before transplantation and herpes zoster events after transplantation was confirmed, whereas rituximab therapy was not associated with herpes zoster events.
Conclusions
Low‐dose rituximab therapy in kidney transplant recipients did not influence herpes zoster development after transplantation. Varicella zoster vaccination before transplantation may play an important role in preventing herpes zoster after transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
- Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan.
ORCID-Profile: Hayato Nishida, Sei Naito, Norihiko Tsuchiya
Zitieren
APA
Nishida, H., Fukuhara, H., Takai, S., Nawano, T., Takehara, T., Narisawa, T., Kanno, H., Yagi, M., Yamagishi, A., Naito, S., & Tsuchiya, N. (2025). Herpes zoster development in living kidney transplant recipients receiving low‐dose rituximab. International Journal of Urology. https://doi.org/10.1111/iju.15600
Vancouver
Nishida H, Fukuhara H, Takai S, Nawano T, Takehara T, Narisawa T, et al. Herpes zoster development in living kidney transplant recipients receiving low‐dose rituximab. International Journal of Urology. 2025. doi:10.1111/iju.15600
BibTeX
@article{Nishida2025,
author = {Nishida, Hayato and Fukuhara, Hiroki and Takai, Satoshi and Nawano, Takaaki and Takehara, Tomohiro and Narisawa, Takafumi and Kanno, Hidenori and Yagi, Mayu and Yamagishi, Atsushi and Naito, Sei and Tsuchiya, Norihiko},
title = {Herpes zoster development in living kidney transplant recipients receiving low‐dose rituximab},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.15600}
}
EUVIMED